Asenapine vs Paliperidone palmitate (Invega Sustenna)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Paliperidone palmitate (Invega Sustenna)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Partial signal

NCT00101634 · Phase 3 · completed

The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.

Next expected readout: December 2026 · NCT07493551 (registry estimate)

Reported efficacy

Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)

Result source: NCT02431702

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapinePaliperidone palmitate (Invega Sustenna)
PANSS total, change-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
CGI-S, change-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
—Not posted · NCT00101634
PSP, change—Not posted · NCT002127718.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351
Relapse (% of patients)—Not posted · NCT00212771—Not posted · NCT00101634

PANSS total, change

Asenapine
-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Paliperidone palmitate (Invega Sustenna)
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769

CGI-S, change

Asenapine
-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Paliperidone palmitate (Invega Sustenna)
-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634

PSP, change

Asenapine
—Not posted · NCT00212771
Paliperidone palmitate (Invega Sustenna)
8.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Asenapine: 5 of 5 rows · Paliperidone palmitate (Invega Sustenna): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapine
Rows use multiple source trials
Paliperidone palmitate (Invega Sustenna)
Rows use multiple source trials
PANSS Total
absolute change · score
No placebo or comparator arm
-11.08 score @ 52wka,b,c,d
NCT01244828 · Phase 3 · registry result, not featured evidence
show 1 more dose
-5.48 score
NCT01244828 · Phase 3 · registry result, not featured evidence
57.4 score @ 13.14wk150 mga,b,c,d
NCT01606254 · Phase 2 · registry result, not featured evidence
show 3 more doses
60.2 score @ 13.14wk100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
60.6 score @ 13.14wk150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
56.4 score @ 13.14wk50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Dropout rate
44.4%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—Part 2-Paliperidone Palmitate (PP)f
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
59.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
6.4%
NCT01081769 · Phase 3 · registry result, not featured evidence
40.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
24.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
44.8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
46.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
48.1%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
28.6%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
14.3%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—Part 2-Paliperidone Palmitate (PP)f
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
2.2%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—
NCT01081769 · Phase 3 · registry result, not featured evidence
17%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
3.1%
NCT00589914 · Phase 3 · registry result, not featured evidence
8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.3%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Serious AEs
0%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
12.8%Part 2-Paliperidone Palmitate (PP)f
NCT02431702 · Phase 3
show 16 more results
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
18.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
5%Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
11.2%
NCT01081769 · Phase 3 · registry result, not featured evidence
6.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
3.9%Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
6.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
—150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
14.3%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailye
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
f
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3
show 16 more results
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3
injection site pain 18.6%
insomnia 18.6%
weight increased 13.3%
NCT01157351 · Phase 4 · registry result, not featured evidence
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
weight increased 15.4%
insomnia 11.2%
headache 10.6%
NCT01081769 · Phase 3 · registry result, not featured evidence
insomnia 17% (placebo 15.2%)
injection site pain 13.2% (placebo 6.7%)
nasopharyngitis 12.6% (placebo 6.1%)
NCT01299389 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.4% (placebo 6.1%)
constipation 5.2% (placebo 5.5%)
insomnia 3.9% (placebo 15.2%)
NCT01299389 · Phase 3 · registry result, not featured evidence
insomnia 9.4%
headache 7.1%
somnolence 5.6%
NCT00589914 · Phase 3 · registry result, not featured evidence
150 mg eq.
injection site pain 8% (placebo 3.7%)
headache 6.1% (placebo 7.3%)
akathisia 5.5% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
100 mg eq.
headache 6.7% (placebo 7.3%)
injection site pain 6.1% (placebo 3.7%)
akathisia 4.8% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
25 mg eq.
headache 10.6% (placebo 7.3%)
injection site pain 8.8% (placebo 3.7%)
akathisia 1.3% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
150 mg
blood prolactin increased 92.9%
insomnia 28.6%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
100 mg
blood prolactin increased 64.3%
psychiatric symptom 42.9%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
150/ 50 mg
blood prolactin increased 71.4%
nasopharyngitis 28.6%
alanine aminotransferase increased 21.4%
NCT01606254 · Phase 2 · registry result, not featured evidence
50 mg
blood prolactin increased 78.6%
nasopharyngitis 35.7%
psychiatric symptom 35.7%
NCT01606254 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 15 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
PANSS 30% 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
0% (n=111) vs 2.1% (n=99) placebo @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 5.1% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 7.1% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
14.4% (n=111) vs 13.1% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
16.2% (n=111) vs 14.1% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
21.6% (n=111) vs 17.2% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49% (n=104) vs 36% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 51 participants as posted
72.1% (n=104) vs 62% (n=100) placebo @ 8.4wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0% (n=96) vs 2.1% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
2.1% (n=96) vs 5.1% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2% (n=96) vs 7.1% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.3% (n=96) vs 13.1% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
10.4% (n=96) vs 14.1% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
15.6% (n=96) vs 17.2% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
50% (n=96) vs 36% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 48 participants as posted
64.2% (n=96) vs 62% (n=100) placebo @ 8.4wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
Weight 1.3 vs 0.3 placebo kg @ 6wk5 mg BID
absolute change · kg
NCT01617187 · Phase 3 · registry result, not featured evidence
show 2 more results
1.3 vs 0.3 placebo kg @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0 vs 2.6 Olanzapine kg @ 26wk
NCT00145496 · Phase 3 · registry result, not featured evidence
CGI-I 33.3% (n=111) vs 37.8% (n=99) placebo @ 0.57wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 19 more results
46.8% (n=111) vs 45.5% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=111) vs 54.5% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.1% (n=111) vs 58.6% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
62.2% (n=111) vs 60.6% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
64% (n=111) vs 64.6% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.6% (n=173) vs 41.4% (n=174) placebo @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
39.4% (n=104) vs 28% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
70.2% (n=178) vs 41.4% (n=174) placebo @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
34.7% (n=96) vs 37.8% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 45.5% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 54.5% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
54.2% (n=96) vs 58.6% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
58.3% (n=96) vs 60.6% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=96) vs 64.6% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
37.5% (n=96) vs 28% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -2.7 vs -2.4 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-4.9 vs -3.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.2 vs -5.4 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.4 vs -6.7 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.2 vs -7.7 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.2 vs -7.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.1 vs -8 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.26 vs 0.19 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-11.5 vs -8.5 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-6.34 vs 0.19 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-2.2 vs -2.4 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.1 vs -5.4 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -6.7 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -7.7 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.8 vs -7.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.9 vs -8.5 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.8 vs -2 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.9 vs -2.8 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.1 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.4 vs -5.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.6 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.7 vs -6.1 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.6 vs -6.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.78 vs -1.37 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-8.9 vs -6.1 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-5.03 vs -1.37 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.8 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -4.1 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.5 vs -5.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -5.6 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.1 vs -6.1 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.8 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.9 vs -1.3 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.8 vs -2 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.2 vs -2.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.7 vs -4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.77 vs -0.41 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-5.3 vs -3.7 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-3.35 vs -0.41 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.7 vs -1.3 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -2 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.6 vs -2.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -3.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -3 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.7 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.4 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -1.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -2.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.7 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.48 vs 0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.4 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.85 vs 0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -2.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.3 vs -0.5 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-0.5 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.9 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.8 vs -1.1 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.77 vs 0.86 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-1.4 vs 0.86 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.5 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -1 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.4 vs -1.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

Paliperidone palmitate (Invega Sustenna)

Time to Treatment Failure NA vs NA Oral Antipsychotics months
time to event · months
NCT02431702 · Phase 3
show 2 more results
NA vs NA Oral Antipsychotics months
NCT02431702 · Phase 3
13.67 vs 7.43 Oral Antipsychotics months*
NCT01157351 · Phase 4 · registry result, not featured evidence · converted to months from 416 days as posted
MCCB Composite 1.6 vs 3.2 Oral Antipsychotics T-score @ 78.2wk
absolute change · T-score
NCT02431702 · Phase 3
show 3 more results
-0.7 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
-0.2 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
2 vs 2.8 Oral Antipsychotics T-score @ 39.1wk
NCT02431702 · Phase 3
PSP 8.3 vs 1.7 placebo score @ 13wk150 mg eq.
absolute change · score
NCT00590577 · Phase 3 · registry result, not featured evidence
show 16 more results
6.1 vs 1.7 placebo score @ 13wk100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.9 vs 1.7 placebo score @ 13wk25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3
5.75 vs 5.36 Oral Antipsychotics score @ 65wk
NCT01157351 · Phase 4 · registry result, not featured evidence
1 vs 1.1 PP3M score @ 52wk
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
4.9 vs 4.3 Oral Antipsychotics score @ 4.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
7.6 vs 7.7 Oral Antipsychotics score @ 13wk
NCT01081769 · Phase 3 · registry result, not featured evidence
9.9 vs 10.8 Oral Antipsychotics score @ 26wk
NCT01081769 · Phase 3 · registry result, not featured evidence
11.4 vs 11.9 Oral Antipsychotics score @ 39wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.7 vs 12.3 Oral Antipsychotics score @ 52wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.9 vs 12.9 Oral Antipsychotics score @ 65wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14 vs 13.3 Oral Antipsychotics score @ 78wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14.7 vs 14 Oral Antipsychotics score @ 91wk
NCT01081769 · Phase 3 · registry result, not featured evidence
15.2 vs 14.6 Oral Antipsychotics score @ 104wk
NCT01081769 · Phase 3 · registry result, not featured evidence
8.5 vs 8.8 RISPERDAL CONSTA score @ 13wk
NCT00589914 · Phase 3 · registry result, not featured evidence
MCCB Working Memory -0.2 vs -0.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-1.7 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Verbal Learning 1.3 vs 1 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.3 vs 0.8 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Speed of Processing 1.8 vs 3.5 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.5 vs 4.9 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Attention/Vigilance 3.2 vs 0.7 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.4 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Visual Learning 1.3 vs 1.4 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.2 vs -0.2 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Reasoning Problem Solving 0.2 vs 2.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
3.4 vs 4.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Social Cognition 0.3 vs 1.6 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-0.2 vs 1.4 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
Time to First Psychiatric Hospitalization or Arrest/Incarceration NA vs 9 Oral Antipsychotics months
time to event · months
NCT01157351 · Phase 4 · registry result, not featured evidence
Time to First Psychiatric Hospitalization NA vs NA Oral Antipsychotics months
time to event · months
NCT01157351 · Phase 4 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Paliperidone palmitate (Invega Sustenna)'s landscape